Compare Quest Diagnostics Inc (DGX) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs IQIYI Inc - ADR — how do they compare? Quest Diagnostics Inc trades at $230.98 (market cap $25.48B), while IQIYI Inc - ADR trades at $1.03 (market cap $974.67M). The key difference: Quest Diagnostics Inc is far larger — about 26.1× IQIYI Inc - ADR's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and IQIYI Inc - ADR for 55 Days on average.
| DGX | IQ | |
|---|---|---|
Market Cap | $25.48B | $974.67M |
Volume | 941,866 | 4,964,108 |
Sector | Health | Media |
52-Week High | $247.45 | $2.35 |
52-Week Low | $173.49 | $0.86 |
Typical Hold Time | 56 Days | 55 Days |
Enterprise Value | $31.23B | $2.47B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
IQ trades at $1.025, up 0.99% today, but technicals are bearish with mixed sentiment. The company reported a net loss of $206.31M in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29B, and profitability metrics like ROE are negative. Analyst consensus is split with 50% buy ratings, but cash flow trends show volatility, and the firm is heavily investing in AI-driven content.
Outlook is cautious; while AI initiatives offer growth potential, core streaming pressures and persistent losses pose risks. The stock's low P/S and P/B suggest undervaluation, but investor confidence hinges on a return to profitability and successful execution of new content strategies amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
